Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880823 | 0.84 | LMNA (0.51) | MAPTSMN1; SMN2LMNA | |
| SCHEMBL5880929 | 0.80 | SMN1; SMN2 (0.33) | MAPTSMN1; SMN2CYP2C9CYP2C19LMNA | |
| SCHEMBL5881125 | 0.79 | S1PR1 (0.40) | SMN1; SMN2FFAR1 | |
| SCHEMBL3991198 | 0.79 | LMNA (0.46) | MAPTSMN1; SMN2LMNA | |
| SCHEMBL8340435 | 0.79 | SMN1; SMN2 (0.35) | MAPTSMN1; SMN2CYP2C9CYP2C19LMNA | |
| SCHEMBL5880743 | 0.79 | SMN1; SMN2 (0.35) | MAPTSMN1; SMN2CYP2C9CYP2C19LMNA | |
| SCHEMBL5880916 | 0.78 | RAB9A (0.45) | SMN1; SMN2FFAR1 | |
| SCHEMBL5880919 | 0.78 | MRGPRX4 (0.34) | — | |
| SCHEMBL5881129 | 0.77 | FFAR1 (0.38) | FFAR1 | |
| SCHEMBL1464640 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | MAPT 2903/4885SMN1; SMN2 3990/4885CYP2C9 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.